Mainz Biomed N.V (MYNZ) said Tuesday it has partnered with Thermo Fisher Scientific (TMO) to develop a colorectal cancer screening test.

Financial details of the partnership were not disclosed.

Mainz said the partnership will combine its experience in mRNA-based colorectal cancer detection with Thermo Fisher's technology resources to develop a non-invasive test for detecting early-stage colorectal cancer and precancerous growths.

Shares of Mainz Biomed rose nearly 7% in recent Tuesday trading, while Thermo Fisher's rose 0.3%.

Price: 0.23, Change: +0.01, Percent Change: +6.51